Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective

Thrombosis Research

Volumn 169, Issue , 2018, Pages 35-40

  Pengo, Vittorio ^a   Denas, Gentian ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiphospholipid antibody syndrome; Cardiolipin; Lupus anticoagulant; Phospholipids; 2 Glycoprotein I

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; AUTOIMMUNE DISEASE; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LABORATORY TEST; PATIENT RISK; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; COMPLICATION; FEMALE; PREGNANCY; PREGNANCY COMPLICATION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; THROMBOSIS;

EID: 85049744795     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2018.07.011     Document Type: Review

References (76)

1. Miyakis, S. et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4 (2006), 295–306, 10.1111/j.1538-7836.2006.01753.x.
2. Denas, G., Jose, S.P., Bracco, A., Zoppellaro, G., Pengo, V., Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun. Rev. 14 (2015), 214–222, 10.1016/j.autrev.2014.11.003.
3. Sciascia, S., Cuadrado, M.J., Khamashta, M., Roccatello, D., Renal involvement in antiphospholipid syndrome. Nat. Rev. Nephrol. 10 (2014), 279–289, 10.1038/nrneph.2014.38.
4. Mayer, M., Cerovec, M., Rados, M., Cikes, N., Antiphospholipid syndrome and central nervous system. Clin. Neurol. Neurosurg. 112 (2010), 602–608, 10.1016/j.clineuro.2010.03.023.
5. Asherson, R.A. et al., Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003), 530–534, 10.1191/0961203303lu394oa.
6. Wilson, W.A. et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42 (1999), 1309–1311, 10.1002/1529-0131(199907)42:7<1309:AID-ANR1>3.0.CO;2-F.
7. Pengo, V. et al., Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J. Thromb. Haemost. 5 (2007), 925–930, 10.1111/j.1538-7836.2007.02454.x.
8. Tripodi, A., Biasiolo, A., Chantarangkul, V., Pengo, V., Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin. Chem. 49 (2003), 1608–1614.
9. Pengo, V. et al., Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb. Res. 120 (2007), 127–133, 10.1016/j.thromres.2006.07.014.
10. Pengo, V. et al., Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J. Thromb. Haemost. 7 (2009), 1737–1740, 10.1111/j.1538-7836.2009.03555.x.
11. Devreese, K.M. et al., Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J. Thromb. Haemost. 12 (2014), 792–795, 10.1111/jth.12537.
12. Devreese, K.M.J., Ortel, T.L., Pengo, V., de Laat, B., Subcommittee on Lupus Anticoagulant/Antiphospholipid, A, Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J. Thromb. Haemost. 16 (2018), 809–813, 10.1111/jth.13976.
13. Tripodi, A., de Groot, P.G., Pengo, V., Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J. Intern. Med. 270 (2011), 110–122, 10.1111/j.1365-2796.2011.02362.x.
14. Giannakopoulos, B., Krilis, S.A., The pathogenesis of the antiphospholipid syndrome. N. Engl. J. Med. 368 (2013), 1033–1044, 10.1056/NEJMra1112830.
15. de Groot, P.G., Meijers, J.C., Beta(2) -Glycoprotein I: evolution, structure and function. J. Thromb. Haemost. 9 (2011), 1275–1284, 10.1111/j.1538-7836.2011.04327.x.
16. de Groot, P.G., Urbanus, R.T., The significance of autoantibodies against beta2-glycoprotein I. Blood 120 (2012), 266–274, 10.1182/blood-2012-03-378646.
17. Meroni, P.L., Borghi, M.O., Raschi, E., Tedesco, F., Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol. 7 (2011), 330–339, 10.1038/nrrheum.2011.52.
18. Hoxha, A., Banzato, A., Ruffatti, A., Pengo, V., Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun. Rev. 16 (2017), 173–178, 10.1016/j.autrev.2016.12.010.
19. Moore, G., Combining, W., Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients. Thromb. J., 5, 2007, 12, 10.1186/1477-9560-5-12.
20. Yamada, H. et al., Prevalence of diverse antiphospholipid antibodies in women with recurrent spontaneous abortion. Fertil. Steril. 80 (2003), 1276–1278.
21. Alijotas-Reig, J., Ferrer-Oliveras, R., Group, E.S., The European registry on obstetric antiphospholipid syndrome (EUROAPS): a preliminary first year report. Lupus 21 (2012), 766–768, 10.1177/0961203312440058.
22. Pengo, V., Biasiolo, A., Rampazzo, P., Brocco, T., dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb. Haemost. 81 (1999), 256–258.
23. Pengo, V. et al., Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. J. Thromb. Haemost. 13 (2015), 782–787, 10.1111/jth.12865.
24. de Laat, B., Derksen, R.H., Urbanus, R.T., de Groot, P.G., IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005), 1540–1545, 10.1182/blood-2004-09-3387.
25. Pengo, V. et al., Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J. Thromb. Haemost. 8 (2010), 237–242, 10.1111/j.1538-7836.2009.03674.x.
26. Pengo, V. et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118 (2011), 4714–4718, 10.1182/blood-2011-03-340232.
27. Pengo, V. et al., Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J. Thromb. Haemost. 11 (2013), 1527–1531, 10.1111/jth.12264.
28. Ruffatti, A. et al., Additional treatments for high-risk obstetric antiphospholipid syndrome: a comprehensive review. Clin. Rev. Allergy Immunol. 53 (2017), 28–39, 10.1007/s12016-016-8571-6.
29. Pengo, V. et al., Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost. 93 (2005), 1147–1152, 10.1160/TH04-12-0839.
30. Pengo, V. et al., A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler. Thromb. Vasc. Biol., 27, 2007, e309-310, 10.1161/ATVBAHA.107.153536.
31. Pengo, V. et al., Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb. Res. 135 (2015), 46–49, 10.1016/j.thromres.2014.10.013.
32. de Groot, P.G. et al., Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J. Thromb. Haemost. 3 (2005), 1993–1997, 10.1111/j.1538-7836.2005.01485.x.
33. Galli, M., Luciani, D., Bertolini, G., Barbui, T., Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003), 1827–1832, 10.1182/blood-2002-02-0441.
34. Urbanus, R.T. et al., Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 8 (2009), 998–1005, 10.1016/S1474-4422(09)70239-X.
35. Buyon, J.P. et al., Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann. Intern. Med. 163 (2015), 153–163, 10.7326/M14-2235.
36. Runchey, S.S., Folsom, A.R., Tsai, M.Y., Cushman, M., McGovern, P.D., Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br. J. Haematol. 119 (2002), 1005–1010.
37. Ruffatti, A. et al., Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J. Thromb. Haemost. 6 (2008), 1693–1696, 10.1111/j.1538-7836.2008.03121.x.
38. Rampazzo, P. et al., Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb. Haemost. 85 (2001), 57–62.
39. de Laat, B. et al., The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J. Thromb. Haemost. 7 (2009), 1767–1773, 10.1111/j.1538-7836.2009.03588.x.
40. Pengo, V. et al., Antibodies to domain 4/5 (Dm4/5) of beta2-Glycoprotein 1 (beta2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb. Res. 136 (2015), 161–163, 10.1016/j.thromres.2015.04.031.
41. Andreoli, L. et al., Anti-beta(2)-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile?. Ann. Rheum. Dis. 70 (2011), 380–383, 10.1136/ard.2010.137281.
42. Andreoli, L. et al., Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against beta2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheum. 67 (2015), 2196–2204, 10.1002/art.39187.
43. Schulman, S., Svenungsson, E., Granqvist, S., Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of anticoagulation study group. Am. J. Med. 104 (1998), 332–338.
44. Kearon, C. et al., Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 133, 2008 (454S-545S) https://doi.org/10.1378/chest.08-0658.
45. Crowther, M.A. et al., A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med. 349 (2003), 1133–1138, 10.1056/NEJMoa035241.
46. Finazzi, G. et al., A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost. 3 (2005), 848–853, 10.1111/j.1538-7836.2005.01340.x.
47. Khamashta, M.A. et al., The management of thrombosis in the antiphospholipid-antibody syndrome. N. Engl. J. Med. 332 (1995), 993–997, 10.1056/NEJM199504133321504.
48. Ruiz-Irastorza, G., Hunt, B.J., Khamashta, M.A., A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 57 (2007), 1487–1495, 10.1002/art.23109.
49. Prandoni, P. et al., Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann. Intern. Med. 150 (2009), 577–585.
50. Palareti, G. et al., D-dimer testing to determine the duration of anticoagulation therapy. N. Engl. J. Med. 355 (2006), 1780–1789, 10.1056/NEJMoa054444.
51. Greaves, M., Cohen, H., MacHin, S.J., Mackie, I., Guidelines on the investigation and management of the antiphospholipid syndrome. Br. J. Haematol. 109 (2000), 704–715.
52. Ruiz-Irastorza, G. et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 20 (2011), 206–218, 10.1177/0961203310395803.
53. Levine, S.R. et al., Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291 (2004), 576–584, 10.1001/jama.291.5.576.
54. Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., Arnesen, H., Warfarin, aspirin, or both after myocardial infarction. N. Engl. J. Med. 347 (2002), 969–974, 10.1056/NEJMoa020496.
55. Okuma, H., Kitagawa, Y., Yasuda, T., Tokuoka, K., Takagi, S., Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int. J. Med. Sci. 7 (2009), 15–18.
56. Dufrost, V., Risse, J., Zuily, S., Wahl, D., Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr. Rheumatol. Rep., 18, 2016, 74, 10.1007/s11926-016-0623-7.
57. Sciascia, S. et al., Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. Rheumatology (Oxford) 55 (2016), 1726–1735, 10.1093/rheumatology/kev445.
58. Cohen, H. et al., Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol, 3, 2016, e426-436, 10.1016/S2352-3026(16)30079-5.
59. Lewis, D.A. et al., Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. Thromb. Res. 135 (2015), 659–665, 10.1016/j.thromres.2015.02.003.
60. Welsby, I., Ortel, T.L., Is it time for individualized thromboprophylaxis regimens in the ICU?. Crit. Care Med. 43 (2015), 500–501, 10.1097/CCM.0000000000000784.
61. Arepally, G.M., Ortel, T.L., Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?. Annu. Rev. Med. 66 (2015), 241–253, 10.1146/annurev-med-051113-024633.
62. Erkan, D., Cervera, R., Asherson, R.A., Catastrophic antiphospholipid syndrome: where do we stand?. Arthritis Rheum. 48 (2003), 3320–3327, 10.1002/art.11359.
63. Asherson, R.A., Cervera, R., Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic?. Autoimmun. Rev. 7 (2008), 164–167, 10.1016/j.autrev.2007.11.009.
64. Kazzaz, N.M., McCune, W.J., Knight, J.S., Treatment of catastrophic antiphospholipid syndrome. Curr. Opin. Rheumatol. 28 (2016), 218–227, 10.1097/BOR.0000000000000269.
65. Emmi, G. et al., An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditions. ScientificWorldJournal, 2014, 2014, 341342, 10.1155/2014/341342.
66. Pontara, E. et al., Thrombocytopenia in high-risk patients with antiphospholipid syndrome. J. Thromb. Haemost. 16 (2018), 529–532, 10.1111/jth.13947.
67. Bortolati, M. et al., Recovery from catastrophic antiphospholipid syndrome by a plasma exchange procedure: report of four cases and review of the literature. Autoimmun. Rev. 8 (2009), 297–301, 10.1016/j.autrev.2008.09.002.
68. Ruffatti, A. et al., Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun. Rev. 6 (2007), 196–202, 10.1016/j.autrev.2006.11.002.
69. Silverman, G.J., Weisman, S., Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48 (2003), 1484–1492, 10.1002/art.10947.
70. Berman, H. et al., Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun. Rev. 12 (2013), 1085–1090, 10.1016/j.autrev.2013.05.004.
71. Fischetti, F. et al., Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 106 (2005), 2340–2346, 10.1182/blood-2005-03-1319.
72. Chitalia, A., Swoboda, D., Broome, C., Management of catastrophic antiphosphopholipid syndrome with eculizumab. Blood, 128, 2016, 2603-2603.
73. Arnaud, L. et al., Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. Autoimmun. Rev., 2017, 10.1016/j.autrev.2017.09.003.
74. Arnaud, L. et al., Efficacy of aspirin for the primary Prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun. Rev. 13 (2014), 281–291, 10.1016/j.autrev.2013.10.014.
75. Nuri, E. et al., Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res. 65 (2017), 17–24, 10.1007/s12026-016-8812-z.
76. Belizna, C., Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun. Rev. 14 (2015), 358–362, 10.1016/j.autrev.2014.12.006.